Intellia Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

NTLA$11.17-7.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTSOF CASH FLOWS

(Amounts in thousands)

	Year Ended December 31,
	2025	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$(412,694)	$(519,021)	$(481,192)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,767	10,285	8,976
Loss (gain) on disposal of property and equipment	527	(76)	72
Accelerated amortization/impairment of right-of-use assets	6,156	-	-
Stock-based compensation	80,219	154,273	134,050
Accretion of investment discounts and premiums	(5,858)	(17,817)	(25,897)
Change in fair value of investments, net	899	32,565	-
(Recognition) deferral of equity method investment intra-entity profit on sales	-	(20,967)	6,624
Loss from equity method investment	-	-	15,633
Change in fair value of contingent consideration	-	-	100
Changes in operating assets and liabilities:
Accounts receivable	(951)	27,939	(32,688)
Prepaid expenses and other current assets	(26,352)	5,184	(27,168)
Operating lease right-of-use assets	33,086	21,466	19,011
Other assets	2,811	917	(707)
Accounts payable	5,987	6,800	2,522
Accrued expenses	(5,271)	(10,383)	6,024
Deferred revenue	(28,111)	(22,076)	(2,778)
Operating lease liabilities	(54,951)	(17,969)	(16,668)
Net cash used in operating activities	(394,736)	(348,880)	(394,086)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(1,129)	(5,778)	(13,985)
Purchases of marketable securities	(322,510)	(935,573)	(904,464)
Sales and maturities of marketable securities	551,670	1,066,918	887,102
Net cash provided by (used in) investing activities	228,031	125,567	(31,347)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock through at-the-market offerings	128,175	176,899	119,795
Proceeds from options exercised	722	5,862	6,599
Issuance of shares through employee stock purchase plan	2,589	2,986	3,929
Net cash provided by financing activities	131,486	185,747	130,323
Net decrease in cash, cash equivalents and restricted cash equivalents	(35,219)	(37,566)	(295,110)
Cash, cash equivalents and restricted cash equivalents, beginning of period	202,787	240,353	535,463
Cash, cash equivalents and restricted cash equivalents, end of period	$167,568	$202,787	$240,353
Reconciliation of cash, cash equivalents and restricted cash equivalents to consolidated balance sheet:
Cash and cash equivalents	$155,464	$189,182	$226,748
Restricted cash equivalents, included in investments and other assets	12,104	13,605	13,605
Total cash, cash equivalents and restricted cash equivalents	$167,568	$202,787	$240,353
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Purchases of property and equipment unpaid at period end	$32	$577	$1,525
Reduction of right-of-use assets from remeasurement of lease liabilities	61,917	-	-
Operating lease liability arising from obtaining right-of-use assets	-	112,821	1,311
Non-cash trade-in of property and equipment	-	99	-
Proceeds from at-the-market offerings unpaid at period end	-	-	2,075
Shares issued for Rewrite contingent consideration	-	-	24,126

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.